The biosynthetic platform provides a potential simple and efficient method for rapidly producing natural

The Company’s clinical safety team has actively monitored ongoing interim data of patients and found there have been no safety concerns.....

The final terms will be agreed to by the parties after the completion of due diligence by Revive - Expected to close on or before Jan.31.21

Liquid Avatar Partners with Fintech Innovator XTM to enable Hospitality, Personal Care and other Sectors to Verify COVID19 Vaccine....

Liquid Avatar, Lumedic, Loop Insights, The Campus Agency and TripXpertz Form Consortium to Manage Verifiable Identity Credentials for COV...

Algernon has reached 25% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study...

Algernon is pleased to announce that it has now enrolled 100 patients, which is two thirds of it enrollment target...

The Company has selected and finalized with five clinical sites in Florida, Texas and California for enrollment of patients in the Phase 3..

Algernon has now enrolled 75 patients, which is 50% of its enrollment target, for its multinational Phase 2b/3 human study of NP-120

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19